Kancera carries out pharmaceutical development, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies.

At present Kancera is primarily developing drugs for the treatment of leukemia and solid tumors, based partly on blocking survival signals in the cancer cell and partly on preventing adaptation of the cancer’s metabolism, thereby making the cancer more susceptible to chemotherapy.